NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

Hui Wang, Xiufei Liu, Min Long, Yi Huang, Linlin Zhang, Rui Zhang, Yi Zheng, Xiaoyu Liao, Yuren Wang, Qian Liao, Wenjie Li, Zili Tang, Qiang Tong, Xiaocui Wang, Fang Fang, Montserrat Rojo De La Vega, Qin Ouyang, Donna Zhang, Shicang Yu, Hongting Zheng

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Cancer is a common comorbidity of diabetic patients; however, little is known about the effects that antidiabetic drugs have on tumors. We discovered that common classes of drugs used in type 2 diabetes mellitus, the hypoglycemic dipeptidyl peptidase-4 inhibitors (DPP-4i) saxagliptin and sitagliptin, as well as the antineuropathic a-lipoic acid (ALA), do not increase tumor incidence but increase the risk of metastasis of existing tumors. Specifically, these drugs induce prolonged activation of the nuclear factor E2-related factor 2 (NRF2)-mediated antioxidant response through inhibition of KEAP1-C151-dependent ubiquitination and subsequent degradation of NRF2, resulting in upregulated expression of metastasis-associated proteins, increased cancer cell migration, and promotion of metastasis in xenograft mouse models. Accordingly, knockdown of NRF2 attenuated naturally occurring and DPP-4i-induced tumor metastasis, whereas NRF2 activation accelerated metastasis. Furthermore, in human liver cancer tissue samples, increased NRF2 expression correlated with metastasis. Our findings suggest that antioxidants that activate NRF2 signaling may need to be administered with caution in cancer patients, such as diabetic patients with cancer. Moreover, NRF2 may be a potential biomarker and therapeutic target for tumor metastasis.

Original languageEnglish (US)
Article number334ra51
JournalScience Translational Medicine
Volume8
Issue number334
DOIs
StatePublished - Apr 13 2016

Fingerprint

NF-E2-Related Factor 2
Hypoglycemic Agents
Antioxidants
Neoplasm Metastasis
Neoplasms
Dipeptidyl-Peptidase IV Inhibitors
Thioctic Acid
Ubiquitination
Liver Neoplasms
Heterografts
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Cell Movement
Comorbidity
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., ... Zheng, H. (2016). NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science Translational Medicine, 8(334), [334ra51]. https://doi.org/10.1126/scitranslmed.aad6095

NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. / Wang, Hui; Liu, Xiufei; Long, Min; Huang, Yi; Zhang, Linlin; Zhang, Rui; Zheng, Yi; Liao, Xiaoyu; Wang, Yuren; Liao, Qian; Li, Wenjie; Tang, Zili; Tong, Qiang; Wang, Xiaocui; Fang, Fang; De La Vega, Montserrat Rojo; Ouyang, Qin; Zhang, Donna; Yu, Shicang; Zheng, Hongting.

In: Science Translational Medicine, Vol. 8, No. 334, 334ra51, 13.04.2016.

Research output: Contribution to journalArticle

Wang, H, Liu, X, Long, M, Huang, Y, Zhang, L, Zhang, R, Zheng, Y, Liao, X, Wang, Y, Liao, Q, Li, W, Tang, Z, Tong, Q, Wang, X, Fang, F, De La Vega, MR, Ouyang, Q, Zhang, D, Yu, S & Zheng, H 2016, 'NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis', Science Translational Medicine, vol. 8, no. 334, 334ra51. https://doi.org/10.1126/scitranslmed.aad6095
Wang, Hui ; Liu, Xiufei ; Long, Min ; Huang, Yi ; Zhang, Linlin ; Zhang, Rui ; Zheng, Yi ; Liao, Xiaoyu ; Wang, Yuren ; Liao, Qian ; Li, Wenjie ; Tang, Zili ; Tong, Qiang ; Wang, Xiaocui ; Fang, Fang ; De La Vega, Montserrat Rojo ; Ouyang, Qin ; Zhang, Donna ; Yu, Shicang ; Zheng, Hongting. / NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. In: Science Translational Medicine. 2016 ; Vol. 8, No. 334.
@article{181a20fd39194d5fbeebc0c8b68555e2,
title = "NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis",
abstract = "Cancer is a common comorbidity of diabetic patients; however, little is known about the effects that antidiabetic drugs have on tumors. We discovered that common classes of drugs used in type 2 diabetes mellitus, the hypoglycemic dipeptidyl peptidase-4 inhibitors (DPP-4i) saxagliptin and sitagliptin, as well as the antineuropathic a-lipoic acid (ALA), do not increase tumor incidence but increase the risk of metastasis of existing tumors. Specifically, these drugs induce prolonged activation of the nuclear factor E2-related factor 2 (NRF2)-mediated antioxidant response through inhibition of KEAP1-C151-dependent ubiquitination and subsequent degradation of NRF2, resulting in upregulated expression of metastasis-associated proteins, increased cancer cell migration, and promotion of metastasis in xenograft mouse models. Accordingly, knockdown of NRF2 attenuated naturally occurring and DPP-4i-induced tumor metastasis, whereas NRF2 activation accelerated metastasis. Furthermore, in human liver cancer tissue samples, increased NRF2 expression correlated with metastasis. Our findings suggest that antioxidants that activate NRF2 signaling may need to be administered with caution in cancer patients, such as diabetic patients with cancer. Moreover, NRF2 may be a potential biomarker and therapeutic target for tumor metastasis.",
author = "Hui Wang and Xiufei Liu and Min Long and Yi Huang and Linlin Zhang and Rui Zhang and Yi Zheng and Xiaoyu Liao and Yuren Wang and Qian Liao and Wenjie Li and Zili Tang and Qiang Tong and Xiaocui Wang and Fang Fang and {De La Vega}, {Montserrat Rojo} and Qin Ouyang and Donna Zhang and Shicang Yu and Hongting Zheng",
year = "2016",
month = "4",
day = "13",
doi = "10.1126/scitranslmed.aad6095",
language = "English (US)",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "334",

}

TY - JOUR

T1 - NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

AU - Wang, Hui

AU - Liu, Xiufei

AU - Long, Min

AU - Huang, Yi

AU - Zhang, Linlin

AU - Zhang, Rui

AU - Zheng, Yi

AU - Liao, Xiaoyu

AU - Wang, Yuren

AU - Liao, Qian

AU - Li, Wenjie

AU - Tang, Zili

AU - Tong, Qiang

AU - Wang, Xiaocui

AU - Fang, Fang

AU - De La Vega, Montserrat Rojo

AU - Ouyang, Qin

AU - Zhang, Donna

AU - Yu, Shicang

AU - Zheng, Hongting

PY - 2016/4/13

Y1 - 2016/4/13

N2 - Cancer is a common comorbidity of diabetic patients; however, little is known about the effects that antidiabetic drugs have on tumors. We discovered that common classes of drugs used in type 2 diabetes mellitus, the hypoglycemic dipeptidyl peptidase-4 inhibitors (DPP-4i) saxagliptin and sitagliptin, as well as the antineuropathic a-lipoic acid (ALA), do not increase tumor incidence but increase the risk of metastasis of existing tumors. Specifically, these drugs induce prolonged activation of the nuclear factor E2-related factor 2 (NRF2)-mediated antioxidant response through inhibition of KEAP1-C151-dependent ubiquitination and subsequent degradation of NRF2, resulting in upregulated expression of metastasis-associated proteins, increased cancer cell migration, and promotion of metastasis in xenograft mouse models. Accordingly, knockdown of NRF2 attenuated naturally occurring and DPP-4i-induced tumor metastasis, whereas NRF2 activation accelerated metastasis. Furthermore, in human liver cancer tissue samples, increased NRF2 expression correlated with metastasis. Our findings suggest that antioxidants that activate NRF2 signaling may need to be administered with caution in cancer patients, such as diabetic patients with cancer. Moreover, NRF2 may be a potential biomarker and therapeutic target for tumor metastasis.

AB - Cancer is a common comorbidity of diabetic patients; however, little is known about the effects that antidiabetic drugs have on tumors. We discovered that common classes of drugs used in type 2 diabetes mellitus, the hypoglycemic dipeptidyl peptidase-4 inhibitors (DPP-4i) saxagliptin and sitagliptin, as well as the antineuropathic a-lipoic acid (ALA), do not increase tumor incidence but increase the risk of metastasis of existing tumors. Specifically, these drugs induce prolonged activation of the nuclear factor E2-related factor 2 (NRF2)-mediated antioxidant response through inhibition of KEAP1-C151-dependent ubiquitination and subsequent degradation of NRF2, resulting in upregulated expression of metastasis-associated proteins, increased cancer cell migration, and promotion of metastasis in xenograft mouse models. Accordingly, knockdown of NRF2 attenuated naturally occurring and DPP-4i-induced tumor metastasis, whereas NRF2 activation accelerated metastasis. Furthermore, in human liver cancer tissue samples, increased NRF2 expression correlated with metastasis. Our findings suggest that antioxidants that activate NRF2 signaling may need to be administered with caution in cancer patients, such as diabetic patients with cancer. Moreover, NRF2 may be a potential biomarker and therapeutic target for tumor metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84963799947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963799947&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aad6095

DO - 10.1126/scitranslmed.aad6095

M3 - Article

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 334

M1 - 334ra51

ER -